166 related articles for article (PubMed ID: 21104004)
1. Physiologically based pharmacokinetic model for topotecan in mice.
Shah DK; Balthasar JP
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):121-42. PubMed ID: 21104004
[TBL] [Abstract][Full Text] [Related]
2. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Shah DK; Balthasar JP
Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
[TBL] [Abstract][Full Text] [Related]
3. Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Loos WJ; Gelderblom H; Verweij J; van Boven-van Zomeren DM; Nooter K; Stoter G; Sparreboom A
Anticancer Drugs; 2003 Mar; 14(3):227-32. PubMed ID: 12634617
[TBL] [Abstract][Full Text] [Related]
4. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.
Shah DK; Balthasar JP
J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):55-69. PubMed ID: 24368689
[TBL] [Abstract][Full Text] [Related]
5. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Zackrisson AL; Malmström H; Peterson C
Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
[TBL] [Abstract][Full Text] [Related]
6. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.
Léger F; Loos WJ; Fourcade J; Bugat R; Goffinet M; Mathijssen RH; Verweij J; Sparreboom A; Chatelut E
Br J Cancer; 2004 Jan; 90(2):343-7. PubMed ID: 14735174
[TBL] [Abstract][Full Text] [Related]
8. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.
de Vries NA; Ouwehand M; Buckle T; Beijnen JH; van Tellingen O
Biomed Chromatogr; 2007 Nov; 21(11):1191-200. PubMed ID: 17582233
[TBL] [Abstract][Full Text] [Related]
9. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Curtis KK; Hartney JT; Jewell RC; Park JW; Lebowitz PF; Griffin PP; Borad MJ; Fitch TR; Northfelt DW
J Clin Pharmacol; 2010 Mar; 50(3):268-75. PubMed ID: 19808951
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.
Davies BE; Minthorn EA; Dennis MJ; Rosing H; Beijnen JH
Pharm Res; 1997 Oct; 14(10):1461-5. PubMed ID: 9358562
[TBL] [Abstract][Full Text] [Related]
11. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.
Shah DK; Shin BS; Veith J; Tóth K; Bernacki RJ; Balthasar JP
J Pharmacol Exp Ther; 2009 May; 329(2):580-91. PubMed ID: 19233938
[TBL] [Abstract][Full Text] [Related]
12. Gender-dependent pharmacokinetics of topotecan in adult patients.
Loos WJ; Gelderblom HJ; Verweij J; Brouwer E; de Jonge MJ; Sparreboom A
Anticancer Drugs; 2000 Oct; 11(9):673-80. PubMed ID: 11129727
[TBL] [Abstract][Full Text] [Related]
13. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
14. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tissue disposition of lenalidomide in mice.
Rozewski DM; Herman SE; Towns WH; Mahoney E; Stefanovski MR; Shin JD; Yang X; Gao Y; Li X; Jarjoura D; Byrd JC; Johnson AJ; Phelps MA
AAPS J; 2012 Dec; 14(4):872-82. PubMed ID: 22956478
[TBL] [Abstract][Full Text] [Related]
16. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
17. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
18. Serum cystatin C is a better marker of topotecan clearance than serum creatinine.
Hoppe A; Séronie-Vivien S; Thomas F; Delord JP; Malard L; Canal P; Chatelut E
Clin Cancer Res; 2005 Apr; 11(8):3038-44. PubMed ID: 15837759
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of intraperitoneal topotecan.
Hofstra LS; Bos AM; de Vries EG; van der Zee AG; Beijnen JH; Rosing H; Mulder NH; Aalders JG; Willemse PH
Br J Cancer; 2001 Nov; 85(11):1627-33. PubMed ID: 11742479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
